TABLE 7.
Activities and spectra of activity of 11 representatives of non-β-lactam drug classes tested against the four most prevalent causes of gram-negative bacteremia in the United States
| Antimicrobial class and agent tested | Activity againsta:
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
E. coli (769)
|
Klebsiella (311)
|
P. aeruginosa (189)
|
Enterobacter (151)
|
|||||||||
| MIC range | MIC50/ MIC90 | % S | MIC range | MIC50/ MIC90 | % S | MIC range | MIC50/ MIC90 | % S | MIC range | MIC50/ MIC90 | % S | |
| Aminoglycosides | ||||||||||||
| Amikacin | 1–>32 | 4/8 | 98.5 | ≤0.25–32 | 2/4 | 99.0 | ≤0.25–>32 | 4/8 | 98.4 | ≤0.25–16 | 2/4 | 100 |
| Gentamicin | ≤0.12–>16 | 1/2 | 96.0 | ≤0.12–>16 | 1/1 | 95.3 | ≤0.12–>16 | 2/8 | 89.7 | 0.25–>16 | 1/2 | 94.3 |
| Tobramycin | ≤0.12–>16 | 1/2 | 96.7 | ≤0.12–>16 | 1/1 | 95.1 | ≤0.12–>16 | 1/2 | 95.7 | 0.25–>16 | 1/2 | 93.9 |
| Fluoroquinolones | ||||||||||||
| Ciprofloxacin | ≤0.015–>2 | ≤0.015/0.03 | 97.2 | ≤0.015–>2 | 0.03/0.25 | 96.3 | 0.03–>2 | 0.12/2 | 89.1 | ≤0.015–>2 | 0.03/0.5 | 92.2 |
| Ofloxacin | ≤0.03–>4 | 0.06/0.12 | 97.1 | ≤0.03–>4 | 0.12/0.5 | 96.1 | 0.12–>4 | 1/>4 | 80.6 | ≤0.03–>4 | 0.12/2 | 91.2 |
| Levofloxacin | ≤0.5–>4 | ≤0.5/≤0.5 | 97.6 | ≤0.05–>4 | ≤0.5/≤0.5 | 97.7 | ≤0.5–>4 | ≤0.5/4 | 84.9 | ≤0.5–>4 | ≤0.5/1 | 93.2 |
| Sparfloxacinc | ≤0.25–>2 | ≤0.25/≤0.25 | —b | ≤0.25–>2 | ≤0.25/≤0.25 | — | ≤0.25–>2 | 1/>2 | — | ≤0.25–>2 | ≤0.25/1 | — |
| Gatifloxacinc | ≤0.03–>4 | ≤0.03/0.06 | — | ≤0.03–>4 | 0.12/0.25 | — | 0.25–>4 | 1/>4 | — | ≤0.03–>4 | 0.06/0.5 | — |
| Trovafloxacinc | ≤0.03–>4 | ≤0.03/0.12 | — | ≤0.03–>4 | 0.12/0.5 | — | 0.06–>4 | 0.5/4 | — | ≤0.03–>4 | 0.12/0.5 | — |
| Others | ||||||||||||
| Tetracycline | ≤4–>8 | ≤4/>8 | 72.5 | ≤4–>8 | ≤4/8 | 85.4 | ≤4–>8 | >8/>8 | 3.3 | ≤4–>8 | ≤4/8 | 83.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5–>1 | ≤0.5/>1 | 74.3 | ≤0.5–>1 | ≤0.5/>1 | 87.4 | ≤0.5–>1 | >1/>1 | 2.2 | ≤0.5–>1 | ≤0.5/>1 | 84.4 |